Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis

Osteoporosis International

Volumn 27, Issue 6, 2016, Pages 2117-2126

  Chen, C H ^a,b,c   Lin, C L ^d,e   Kao, C H ^d,f  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Gastroesophageal reflux disease (GERD); Hip fracture; Osteoporosis; Proton pump inhibitor (PPI)

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HIP FRACTURE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPOROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; HEALTH SURVEY; INCIDENCE; RISK FACTOR;

ADULT; AGED; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; POPULATION SURVEILLANCE; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84957649268     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-016-3510-1     Document Type: Article

References (44)

1. Rachner T, Khosla S, Hofbauer L (2011) New horizons in osteoporosis. Lancet 377:1276–1287
2. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41–52
3. Kinsella K, Wan H (2009) International Population Reports, p 95/09–1, An aging world: 2008. US Census Bureau, US Government Printing Office, Washington, DC
4. Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27:125–129
5. Vakil N, van Zanten SV, Kahrlas P, Dent J, Jones R (2006) The Montrel definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920
6. Jung HK (2011) Epidemiology of gastroesophageal reflux disease in Asia: a systemic review. J Neurogastroenterol Motil 17:14–27
7. Bredenoord AJ, Pandolfino JE, Amout AJPM (2013) Gastro-oesophageal reflux disease. Lancet 381:1933–1942
8. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ (2009) Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanisms rather than caustic acid injury. Gastroenterology 137:1776–1784
9. Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Cho SW, Lee KM, Hahm KB (2001) Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 49:364–371
10. Dent J, El-Serag HB, Wallander MA, Johnsson S (2005) Epidemiology of gastro-oesophageal reflux disease: a systemic review. Gut 54:710–717
11. Lim SL, Goh WT, Lee JM, Ng TP, Ho KY, Community Medicine GI Study Group (2005) Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol 20:995–1001
12. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC (2003) Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 18:595–604
13. Chen M, Xiong I, Chen H, Xu A, He L, Hu P (2005) Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol 40:759–767
14. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326
15. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83
16. Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904
17. Database NHIR. Taiwan, http://nhird.nhri.org.tw/en/Background.html (cited in 2015)
18. Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443
19. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P (2005) Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol 162:454–460
20. Menon S, Jayasena H, Nightingale P, Trudgill NJ (2011) Influence of age and sex on endoscopic findings of gastrooesophageal reflux disease: an endoscopy database study. Eur J Gastroenterol Hepatol 23:389–395
21. Achem SR, DeVault KR (2014) Gastroesophageal reflux disease and the elderly. Gastroenterol Clin N Am 43:147–160
22. Sossalla S, Schotola H, Schmitto J, Toischer K, Sihns C, Schworer H, Hasenfuss G, Maier L, Schillinger W (2011) Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium. J Cardiovasc Surg 52:437–444
23. Khinchi P, Saha S, Saraf SA, Kaithwas G (2014) Combination therapy of gamma-aminobutyric acid derivative promotes proton pump inhibitor based healing of reflux esophagitis in animal model. Pharmacol Rep 66:165–168
24. Hall SD, Prokic EJ, McAllister CJ, Ronnqvist KC, Williams AC, Yamawaki N, Witton C, Woodhall GL, Stanford IM (2014) GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson’s disease. Neuroscience 281:68–76
25. Sung HY, Park JW, Kim JS (2014) The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease. J Mov Disord 7:7–12
26. Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42(suppl 3):8–12
27. Zhang J, Cui PL, Lv D, Yao SW, Xu YQ, Yang ZX (2011) Gastroesophageal reflux in cirrhotic patients without esophageal varices. World J Gastroenterol 17:1753–1758
28. Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007) Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Mol Cell Biol 8:722–728
29. Armas LAG, Recker RR (2012) Pathophysiology of osteoporosis. Endocrinol Metab Clin N Am 41:475–486
30. Ilic K, Obradovic N, Vujasinovic-Stupar N (2013) The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 92:217–227
31. Bagger YZ, Rasmussen HB, Alexandersen P, Werge T, Christiansen C, Tanko LB, PERF study group (2007) Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int 18:505–512
32. Pirih F, Lu J, Ye F, Bezouglaia O, Atti E, Ascenzi MG, Tetradis S, Demer L, Aghaloo T, Tintut Y (2012) Adverse effects of hyperlipidemia on bone regeneration and strength. JBMR 27:309–318
33. Nakchbandi IA, Osteoporosis and fractures in liver disease (2014) Relevance, pathogenesis and therapeutic implications. World J Gastroenterol 20:9427–9438
34. Weinstein RS (2012) Glucocorticoid-induced osteoporosis and osteonecrosis. Endocinol Metab Clin N Am 41:595–611
35. Pack AM, Morrell MJ (2004) Epilepsy and bone health in adults. Epilepsy Behav 5(suppl 2):S24–S29
36. Hill DD, Cauley JA, Sheu Y, Bunker CH, Patrick AL, Baker CE, Beckles GLA, Wheeler VW, Zmuda JM (2008) Correlates of bone mineral density in men of African ancestry: the Tobago Bone Health Study. Osteoporos Int 19:227–234
37. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Study. Osteoporos Int 24:1161–1168
38. Hinson AM, Wilkerson BM, Rothman-Fitts I, Rggs AT, Stack BC, Bodenner DL (2015) Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc 63:2070–2073
39. Soloman DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS (2015) Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a Swan cohort study. JBMR 30:232–239
40. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitors use, hip fracture, and changes in bone mineral density in postmenopausal women. Arch Intern Med 170:765–771
41. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589
42. Armour KJ, Armour KE, van’t Hof RJ, Reid DM, Wei XQ, Liew FY, Ralston SH (2001) Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 44:2790–2796
43. Sertorio JT (2013) Proton pump inhibitors and nitric oxide mechanisms in type 2 diabetes. Diabetologia 56:2763–2764
44. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953